Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HGI-001 in Beta-Thalassemia Major
NCT05745532Phase 1Recruiting
- Sponsor
- Shenzhen Hemogen Therapeutic Co., Ltd.
- Start
- Dec 2020
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LentiHBBT87Q in beta thalassemia, sponsored by Shenzhen Hemogen Therapeutic Co., Ltd. Primary endpoints: Frequency and severity of adverse events (AEs) and serious adverse events (SAEs), Overall survival and 3 more. Started Dec 2020; status: recruiting.
02
Drugs
LentiHBBT87Q
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05745532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745532.